What is the latest launch price of cabozantinib in China in 2025?

Cabozantinib (Cabozantinib) is a multi-target tyrosine kinase inhibitor mainly used to treat various malignant tumors such as renal cell carcinoma and thyroid cancer. Although it has been marketed in many countries and regions around the world, as of 2025, cabozantinib has not been officially approved for marketing in China. Therefore, domestic patients are temporarily unable to purchase the drug domestically through formal channels and must resort to overseas formal channels for procurement.

Currently, there are many original drug versions of cabozantinib on the overseas market, including the European version, Hong Kong version, Japanese version and Turkish version. The prices of these original drugs are relatively high, with the latest selling prices ranging from more than 20,000 yuan to more than 50,000 yuan. The price difference is mainly affected by factors such as supply area, specifications, and import taxes. If patients choose to import original drugs, the financial burden will be heavier.

In addition to the original drug, generic versions of cabozantinib have been launched in countries such as Laos and Bangladesh. The ingredients and efficacy of these generic drugs are basically the same as those of the original drugs, and their specifications include 20 mg 90 tablets, 60 mg 30 tablets, 80 mg * 30 tablets, etc. The price of generic drugs is significantly lower than that of original drugs, usually between more than 500 yuan to more than 1,000 yuan, providing patients with more economical medication options.

In general, 2025 Cabozantinib has not yet been launched in China, and patients can purchase original or generic drugs through regular overseas channels. Considering the price difference and medication needs, patients should choose the appropriate specifications and versions under the guidance of their doctors to ensure safety and efficacy. In the future, as the approval process accelerates, cabozantinib is expected to be launched in China and included in medical insurance, which will greatly improve patient accessibility.

Reference materials:https://www.drugs.com/